Oxford Nanopore Technologies has cut its first-half losses sharply and improved cost guidance, though its shares remain well below year-ago levels after a revenue warning earlier in 2026.

Oxford Nanopore Technologies (LSE:ONT), the Oxford-based developer of DNA and RNA sequencing platforms, has spent much of 2026 trying to rebuild investor confidence after a bumpy period for its shares. Its interim results for the six months to 30 June, published on 19 August, showed meaningful progress on profitability, sending the shares up 9.0% to 133.2p on the day. Even after that rebound, the stock was about 36% lower than a year earlier.

Revenue rose 11% to £116.7m, or 12% at constant currency, in line with expectations that the company had lowered in July. Gross profit increased 18% to £72.6m, lifting the gross margin to 62.2% from 58.2%. The pre-tax loss narrowed to £44.9m from £69.0m, while the adjusted EBITDA loss shrank to £22.1m from £48.3m, considerably better than the consensus forecast of a £38.1m loss. The sharp reduction in losses reflected both the higher gross margin and tighter control of operating expenses, suggesting that the company's efforts to reshape its cost base are beginning to deliver tangible results.

A Difficult Year for Sentiment

The improvement follows a series of setbacks. In early March, the shares fell around 10% after the company guided to constant-currency revenue growth of 21% to 25% for 2026, below its earlier ambition of more than 30% compound annual growth over 2024 to 2027. A further warning in July that first-half revenue would miss expectations triggered another sharp fall in the share price.

Regional performance in the first half was mixed. Revenue in Europe, the Middle East, Africa and India rose 24% at constant currency and the Americas grew 13%, but Asia Pacific declined 8.4%, including a 16% fall in China. By customer segment, clinical revenue jumped 35% and biopharma rose 25%, while industrial and research customers grew more modestly at 6.2% and 5.4% respectively.

Cost Discipline and Guidance

Cost control has been a central theme. Adjusted operating costs fell 6.9% year on year and 9.6% compared with the second half of 2025. The company now expects full-year adjusted operating costs to be flat to down 2%, an improvement on earlier guidance of 0% to 5% growth.

For 2026 as a whole, Oxford Nanopore (LSE:ONT) guided to constant-currency revenue growth of 16% to 20% and a gross margin of around 62%. Chief executive Francis Van Parys said the business was tracking well towards adjusted EBITDA breakeven in the 2027 financial year. The company expects to turn free cash flow positive in 2028 and continues to target revenue of more than $700m by 2030.

What Investors Are Watching

The investment debate centres on whether Oxford Nanopore can return to faster top-line growth while keeping costs in check. Clinical and biopharma adoption are seen as the most promising drivers, given the technology's ability to produce long reads and real-time results, while weaker academic research budgets and soft demand in China have held back growth. Competition in sequencing remains intense, with several larger rivals investing heavily in their own platforms.

The next key milestone is the full-year trading update, expected early in 2027, which will show whether second-half revenue has met the narrowed guidance range and whether the path to breakeven remains on schedule.